

## DAFTAR PUSTAKA

- Alit, M. D., 2016. *Keefektifan Pemberian Clozapin Dibandingkan Risperidon Terhadap Panss dan Kadar Interleukin-2 pada Pasien Skizofrenia Kronis Eksaserbasi Akut*. Surakarta: s.n.
- Alphs, L. D., 2020. *The 16-item Negatif Symptom Assessment (NSA-16) Manual*. US: NSA-16 ©.
- Alphs, L. D., Summerfelt, A., Lann, H. & Muller, R. J., 1989. The Negatif Symptom Assessment: A New Instrument to Assess Negatif Symptoms in Schizophrenia. *Psychopharmacology Bulletin*, 25(2), pp. 159-163.
- Andreasen, N. C., 1989. The Scale for the Assessment of Negatif Symptoms (SANS): Conceptual and Theoretical Foundations. *British Journal of Psychiatry*, 155(7), pp. 49-52.
- Axelrod, B. N., Goldman, R. S. & Alphs, L. D., 1993. Validation of the 16-item Negatif Symptom Assessment. *J Psychiatr Res*, 27(3), pp. 253-258.
- Cerveri, G., Gesi, C. & Mencacci, C., 2019. Pharmacological treatment of negatif symptoms in schizophrenia: update and proposal of a clinical algorithm. *Neuropsychiatr Dis Treat*, Volume 15, pp. 1525-1535.
- Chee, J. D., 2018. *Pearson's Product-Moment Correlation: Sample Analysis*, Hawaii: The Queen's Medical Center.
- Chen, J., Cao, H., Meyer-Lindenberg, A. & Schwarz, E., 2018. Male increase in brain gene expression variability is linked to genetic risk for schizophrenia. *Translational Psychiatry*, Volume 8, p. 140.
- Cureton, E. E. & D'Agostino, R. B., 1993. *Factor Analysis An Applied Approach*. 2nd Edition ed. New York: Psychology Press.
- Cureton, E. E. & D'Agostino, R. B., 1993. *Factor Analysis An Applied Approach*. 2nd Edition ed. New York: Psychology Press.
- Darsana, I. W. & Suariyani, N. L. P., 2020. Trend Karakteristik Demografi Pasien Skizofrenia di Rumah Sakit Jiwa Provinsi Bali (2013-2018). *Arc. Com. Health*, 7(1), pp. 41-51.

- Garcia-Alvarez, L. et al., 2018. Spanish validation of the Negatif Symptom Assessment-16 (NSA-16) in patients with schizophrenia. *Revista de Psiquiatria y Salud Mental*, 11(3), pp. 169-175.
- Haro, J. et al., 2003. The Clinical Global Impression– Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. *Acta Psychiatr Scand* , 107(416), pp. 16-23.
- Holm, M. et al., 2020. Employment among people with schizophrenia or bipolar disorder: A population-based study using nationwide registers. *Acta Psychiatrica Scandinavica*, Volume 143, pp. 61-71.
- Huang, B.-J. et al., 2020. Validation of the Chinese Version of the 16-Item Negatif Symptom Assessment. *Neuropsychiatric Disease and Treatment Volume*, Volume 16, pp. 1113-1120.
- Idaiani, S. et al., 2019. Prevalensi Psikosis di Indonesia berdasarkan Riset Kesehatan Dasar 2018. *Jurnal Penelitian dan Pengembangan Pelayanan Kesehatan*, 3(1).
- Kay, S. R., Fiszbein, A. & Opler, L. A., 1987. The Positive and Negatif Syndrome Scale (PANSS) for Schizophrenia. *Schizophrenia Bulletin*, 13(2), pp. 261-276.
- Kirkpatrick, B. et al., 2011. The Brief Negatif Symptom Scale: Psychometric Properties. *Schizophrenia Bulletin*, 37(2), pp. 300-305.
- Kirkpatrick, B., Fenton, W. S., Carpenter, Jr, W. T. & Marder, S. R., 2006. The NIMH-MATRICES Consensus Statement on Negatif Symptoms. *Schizophrenia Bulletin*, 32(2), pp. 214-219.
- Kring, A. M. et al., 2013. The Clinical Assessment Interview for Negatif Symptoms (CAINS): Final Development and Validation. *Am J Psychiatry*, 170(2), pp. 165-172.
- McHugh, M. L., 2012. Interrater Reliability: The Kappa Statistic. *Biochemia Medica*, 22(3), pp. 276-282.
- McHugh, M. L., 2012. Interrater reliability: the kappa statistic. *Biochemia Medica*, 3(22), pp. 276-282.

- Orrico-Sánchez, A., López-Lacort, M. & Muñoz-Qui, C., 2020. Epidemiology of schizophrenia and its management over 8-years period using real-world data in Spain. *BMC Psychiatry*, Volume 20, p. 149.
- Osborne, J. W., 2014. *Best Practices in Exploratory Factor Analysis*. California: CreateSpace Independent Publishing.
- Pedersen, C. B. et al., 2022. Urban-Rural Differences in Schizophrenia Risk: Multilevel Survival Analyses of Individual- and Neighborhood-Level Indicators, Urbanicity and Population Density in a Danish National Cohort Study. *Schizophrenia Bulletin Open*, 3(1).
- Putri, V. S. & Soewadi, 2013. *Hubungan Tingkat Pendidikan Dengan Kejadian Skizofrenia Di Rumah Sakit Ghrasia Yogyakarta Tahun 2012*, Yogyakarta: Universitas Islam Indonesia.
- Rekhi, G., Alphs, L. D., Ang, M. S. & Lee, J., 2019. Clinical utility of the Negatif Symptom Assessment-16 in individuals with schizophrenia. *European Neuropsychopharmacology*, Volume 000, pp. 1-9.
- Retnawati, H., 2017. *Validitas Instrumen*. 2 ed. Yogyakarta: Parama Publishing.
- Ruopp, M. D., Perkins, N. J., Whitcomb, B. W. & Schisterman, E. F., 2008. Youden Index and Optimal Cut-Point Estimated from Observations Affected by a Lower Limit of Detection. *Biom J*, 50(3), p. 419–430.
- Stahl, S. M., 2013. Psychosis and Schizophrenia. In: *Stahl's Essential Psychopharmacology*. Newyork: Cambridge University Press, p. 79.
- Strauss, M. E. & Smith, G. T., 2009. Construct validity: advances in theory and methodology. *Annu Rev Clin Psychol*, Volume 5, pp. 1-25.
- Sugiyono, 2019. *Statistika untuk penelitian*. Bandung: Alfabeta.
- Taherdoost, H., 2016. Validity and Reliability of the Research Instrument; How to Test the Validation of a Questionnaire/Survey in a Research. *SSRN Electronic Journal*, 5(3), pp. 28-36.
- Velligan, D. I. et al., 2009. Association Between Changes on The Negatif Symptom Assessment Scale (NSA-16) and Measures of Functional Outcome in Schizophrenia. *Psychiatry Research*, 169(2), pp. 97-100.